My sister, Professor Jenny Basil (in red), is the Associate Director of Community Outreach for this terrific and growing initiative.

The Brooklyn College Cancer Center, BCCC-CURE, will be training, building, and supporting its network for the next generation of diverse cancer researchers thanks to a $2.6 million grant from the American Cancer Society.

Specifically, the Diversity in Cancer Research Institutional Development Grant (DICR IDG) titled “Supporting Cancer Research at Brooklyn College Cancer Center, a Highly Diverse Institution,” will support early career cancer researchers through $2.6 million over four years. The funding will go toward four areas: pilot grants for faculty who are in the early years of their tenure track; support for clinical scientists’ research and training; and offerings of two postdoctoral fellowships and six master’s scholarships over the length of the grant program.

Other funding earmarked for the center itself will support the mentoring of junior faculty, clinician scientists, and other early career scientists, travel to conferences for BCCC-CURE researchers, plus trainings and seminars on different areas of cancer research. It will also support the launch of the BCCC-CURE Molecular Modeling Laboratory for Cancer Therapeutics lead by Dr. Emilio Gallicchio, professor of chemistry at Brooklyn College and Dr. Shaneen Singh, professor of biology at the college.

“This grant constitutes a unique opportunity for Brooklyn College and the Brooklyn College Cancer Center to support cancer research activities, most specifically for early career scientists in a moment when we are hiring assistant professors,” said Maria Contel, director and research area leader of BCCC-CURE. “The money will support principal investigators and their research groups and allow us to train new experts in the field of cancer research. The support included in this grant for clinician scientists is key, as we will be able to recruit and collaborate with clinician scientists in research areas like cancer disparities, clinical translation of drugs, or cancer immunology.”